SPRO - Spero Therapeutics Inc
IEX Last Trade
1.365
-0.005 -0.366%
Share volume: 58,378
Last Updated: Fri 30 Aug 2024 09:59:50 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.37
-0.01
-0.37%
Fundamental analysis
22%
Profitability
25%
Dept financing
5%
Liquidity
50%
Performance
15%
Performance
5 Days
0 0%
1 Month
-2.84%
3 Months
-3.52%
6 Months
-17.47%
1 Year
-4.86%
2 Year
55.65%
Key data
Stock price
$1.36
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.99 - $1.89
52 WEEK CHANGE
-$0.10
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/13/2024
Company detail
CEO: Ankit Mahadevia
Region: US
Website: https://sperotherapeutics.com/
Employees: 88
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://sperotherapeutics.com/
Employees: 88
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
spero therapeutics is focused on the development of novel therapies to treat highly resistant bacterial infections. the culture at spero is one of respect, action, collaboration and transparency. spero team members are leaders in the field, and have the ability and desire to be a part of a team. at spero, a feeling that we are part of something groundbreaking and innovative fuels our approach.
Recent news